Call Today: 800-417-9951
Contact us for free information or to start a free case review.
The number of deaths among Avandia® users continues to rise, sparking much controversy among the healthcare community.
The diabetes drug Avandia® has been a topic of concern ever since it hit the market. In fact, there has been more than one study suggesting that Avandia® significantly increases the risk of death among its users.
One of the most recent studies, which was released Nov. 24, 2008, suggested that death rate among patients who use Avandia® is 15 percent higher than those taking Actos (pioglitazone). The same study found the incidence of heart failure to be 13 percent higher among patients using Avandia®. Actos is one of the competing type-2 diabetes drugs on the market.
The controversy surrounding the use of Avandia® dates back to a 2007 analysis of more than 40 studies and nearly 28,000 patients that confirmed that patients who take the Avandia® drug have a much higher death risk due to cardiovascular events.
The analysis, published in the New England Journal of Medicine in May 2007, indicated that patients treated with Avandia® for Type 2 diabetes have a significantly higher risk of dying from a heart-related problem compared to patients who are treated with another diabetes drug or a placebo.
If you are concerned about Avandia®’s death risk, you should consult with a physician as soon as possible. If you have been injured as a result of taking Avandia®, a qualified defective drug lawyer can determine if you are eligible to seek reimbursement for your losses with an Avandia® lawsuit.
Type 2 diabetes affects up to 20 million Americans, and an estimated one million American patients are currently taking Avandia®. The U.S. Food and Drug Administration (FDA) has required that new safety information be added to the drug’s label to warn users and healthcare professionals of Avandia®’s death risk and other serious side effects.
People with Type 2 diabetes already have an increased risk of cardiovascular problems, and taking a drug that provides an increased risk of heart attack and other heart problems could lead to deadly complications. In fact, the new meta-analysis of Avandia® data revealed a 30 to 40 percent increased risk of heart attack in patients treated with Avandia®, some of which proved fatal.
When the NEJM published the new safety analysis, the FDA came under harsh new criticism over Avandia®’s death risk and heart attack risk—with documents revealing that the FDA was aware of Avandia®’s risks as early as 2000. Still, GlaxoSmithKline was allowed to continue marketing—and reaping exorbitant profits from sales of—Avandia®.
Evidence shows that Glaxo knew about the dangers, including heart attack and death, associated with its blockbuster drug. Because the company sacrificed safety to profits, it may be held liable for damages suffered by those harmed by Avandia®.
If your loved one died while using Avandia®, your losses should not go silenced. You should consult with an experienced Avandia® attorney to learn more about your legal rights and options. Recoverable damages often include:
To learn more about your legal rights from an experienced product liability attorney, contact us today.
The FDA announced that is has made a change regarding cardiovascular risks to the Avandia® (rosiglitazone) label and patient Medication Guide, Feb. 4, 2011.
The FDA announcement also said that Avandia®'s drug label was updated ...
A government run diabetes trial was halted 18 months early after a safety analysis revealed an increased risk of death in patients whose blood sugar levels dipped too low.
The 10,000 patient trial was examining the effectiveness of aggressive ...
A new study published in the Journal of the American Medical Association reaffirms previous findings about the diabetes drug Avandia—that is, it carries a significantly increased risk of heart failure, heart attack, and death.
Ob...
Copyright © 2001 - 2012 Online Lawyer Source | Legal Marketing Site Designed by eJustice
ATTORNEY ADVERTISEMENT—Thank you for your visit. The content published on this website was not written by medical professionals and should not, at any point, be mistaken for medical advice. Furthermore, the information on this site is intended for educational purposes only and should never interfere with a patient/site visitor and his or her healthcare provider. In addition, viewing the content on this website, requesting additional information, or transmitting information through a contact form should never be considered the formation of an attorney-client relationship. The material published on this site is general and may not apply to your specific circumstances. Every case comes with its own set of unique circumstances; past success discussed on this site does not guarantee future performance. Information found on this website should not be used as incentive to act without seeking counsel from a professional. For more information, please read our disclaimer.